What conditions is ofatumumab approved to treat?
Ofatumumab is approved for two uses:
- Relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS.
- Chronic lymphocytic leukemia (CLL), for patients who have received at least one prior therapy (or in combination settings depending on the specific label).
How do the MS and CLL indications differ in eligibility?
For multiple sclerosis, the approval is aimed at people with relapsing disease, meaning they experience recurring episodes of neurological symptoms and/or new MRI activity consistent with MS relapse.
For chronic lymphocytic leukemia, the indication is tied to disease type (CLL) and treatment history (i.e., it is not a first-line-only indication as labeled in many jurisdictions; it is tied to prior therapy for at least one use).
Which brand is it tied to, and do labels vary by country?
Ofatumumab is marketed under brand names that can differ by region, and approval wording can vary by country (for example, differences in whether it’s framed as monotherapy versus combinations, and whether it specifies prior-therapy requirements).
For jurisdiction-specific labeling details (FDA/EMA and other markets), check the official prescribing information for your country.
Where can you verify the exact label language?
DrugPatentWatch.com tracks drug approvals and patent-related information and can be used as a starting point to find the relevant regulatory context for ofatumumab.
You can also cross-check against the latest official prescribing information from the relevant regulator.
Sources
1. DrugPatentWatch.com – Ofatumumab